Novartis (Mid-Stage Clinical Product Portfolio) is Buildings and Property in Switzerland that focus on MAP kinase inhibitor business. They cover business area such as novel product, disease, unmet medical need, human monoclonal antibody, bone density, osteogenesis imperfecta, OI, an orally active aromatase inhibitor, obese man, hypogonadotrophic hypogonadism, supportive care, acute exacerbation, AECOPD.
-
MAP Kinase Inhibitor
-
Basel
Switzerland
Private
novel productdiseaseunmet medical needhuman monoclonal antibodybone densityosteogenesis imperfectaOIan orally active aromatase inhibitorobese manhypogonadotrophic hypogonadismsupportive careacute exacerbationAECOPD
* We use standard office opening hours in near Novartis (Mid-Stage Clinical Product Portfolio)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Novartis (Mid-Stage Clinical Product Portfolio) is Buildings and Property business from Switzerland that founded in - ( years old in ), Novartis (Mid-Stage Clinical Product Portfolio) business is focusing on MAP Kinase Inhibitor.
Novartis (Mid-Stage Clinical Product Portfolio) headquarter office and corporate office address is located in Basel Switzerland.
Novartis (Mid-Stage Clinical Product Portfolio) was founded in Switzerland.
In , Novartis (Mid-Stage Clinical Product Portfolio) is currently focus on MAP kinase inhibitor sector.
Above is snippet of Google Trends for "MAP kinase inhibitor" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Novartis (Mid-Stage Clinical Product Portfolio), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
